Establishing the Frontline Monotherapy Backbone in EGFR-Mutant NSCLC

This segment examines single-agent osimertinib as the foundation of first-line EGFR-mutated NSCLC therapy and the benchmark against which combination strategies are measured. The faculty review the pivotal monotherapy experience, emphasizing that the large majority of patients with classic sensitizing mutations respond, while the key variable is durability rather than response itself. They highlight osimertinib's strong central nervous system activity, a meaningful advance over earlier-generation tyrosine kinase inhibitors, and its generally favorable tolerability, with uncommon but important cardiac and pneumonitis risks and typically manageable gastrointestinal and skin effects. A recurring theme is quality of life, since many patients respond while living largely as they did before diagnosis. The discussion frames monotherapy's central challenge: identifying which patients are likely to be durable, long-term responders versus those whose risk features warrant earlier intensification, setting up the combination regimens explored next. It offers a grounded, practical reference point for treatment selection.